Secondly, the discovery of the FSTL1 as a novel target opens new avenues, potentially reducing the cytotoxic side effects associated with traditional drugs used in the treatment of advanced cSCC. This evidence concerns the gene FSTL1 and skin squamous cell carcinoma.